3 of Wall Street’s Favorite Stocks with Questionable Fundamentals

The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.

At StockStory, we look beyond the headlines with our independent analysis to determine whether these bullish calls are justified. That said, here are three stocks where Wall Street’s enthusiasm may be misplaced and some other investments worth exploring instead.

Omnicell (OMCL)

Consensus Price Target: $61.29 (59.5% implied return)

Driven by the vision of an "Autonomous Pharmacy" with zero medication errors, Omnicell (NASDAQ:OMCL) provides medication management automation and adherence tools that help healthcare systems and pharmacies reduce errors and improve efficiency.

Why Do We Avoid OMCL?

1. Muted 5.4% annual revenue growth over the last two years shows its demand lagged behind its healthcare peers
2. Incremental sales over the last five years were much less profitable as its earnings per share fell by 6.8% annually while its revenue grew
3. Below-average returns on capital indicate management struggled to find compelling investment opportunities, and its decreasing returns suggest its historical profit centers are aging

At $38.44 per share, Omnicell trades at 20.7x forward P/E. Read our free research report to see why you should think twice about including OMCL in your portfolio.

Privia Health (PRVA)

Consensus Price Target: $31.42 (32.1% implied return)

Operating in 13 states and the District of Columbia with over 4,300 providers serving more than 4.8 million patients, Privia Health (NASDAQ:PRVA) is a technology-driven company that helps physicians optimize their practices, improve patient experiences, and transition to value-based care models.

Why Is PRVA Not Exciting?

1. Revenue base of $2.25 billion puts it at a disadvantage compared to larger competitors exhibiting economies of scale
2. Low free cash flow margin of 5% for the last five years gives it little breathing room, constraining its ability to self-fund growth or return capital to shareholders
3. ROIC of -0.6% reflects management’s challenges in identifying attractive investment opportunities

Privia Health’s stock price of $23.79 implies a valuation ratio of 21.7x forward P/E. Dive into our free research report to see why there are better opportunities than PRVA.

U.S. Physical Therapy (USPH)

Consensus Price Target: $93.67 (47.8% implied return)

With a nationwide footprint spanning 671 clinics across 42 states, U.S. Physical Therapy (NYSE:USPH) operates a network of outpatient physical therapy clinics and provides industrial injury prevention services to employers across the United States.

Why Are We Hesitant About USPH?

1. Subscale operations are evident in its revenue base of $795.5 million, meaning it has fewer distribution channels than its larger rivals
2. Earnings per share were flat over the last five years while its revenue grew, showing its incremental sales were less profitable
3. Waning returns on capital imply its previous profit engines are losing steam

U.S. Physical Therapy is trading at $63.36 per share, or 21.2x forward P/E. To fully understand why you should be careful with USPH, check out our full research report (it’s free).

Stocks We Like More

ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.

Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.